JIP-1 (153-163)

Product Name:JIP-1 (153-163)

Synonyms:TI-JIP

CAS No:438567-88-5

Purity:95%

Molar Mass:1341.6

Chemical Formula:C61H104N20O14

Storage:Store at -20 degrees Celsius

Sequence:RPKRPTTLNLF

Application:

JIP-1 (153-163) is a synthetic peptide fragment derived from the JNK-interacting protein 1 (JIP-1), corresponding to amino acids 153-163 of the full protein. JIP-1 is a scaffold protein that plays a crucial role in the c-Jun N-terminal kinase (JNK) signaling pathway, which is involved in various cellular processes such as stress responses, apoptosis, and neuronal function. The JIP-1 (153-163) fragment is often used in research to study the interactions between JIP-1 and other components of the JNK signaling cascade, as well as to explore the regulatory mechanisms that control JNK activity. This peptide can help elucidate the role of JIP-1 in neurodegenerative diseases, inflammation, and cancer, providing insights into potential therapeutic strategies targeting the JNK pathway.

Current Research:

JIP-1 (153-163), a segment derived from the JNK-interacting protein-1 (JIP-1), plays a crucial role in modulating the mitogen-activated protein kinase (MAPK) pathway, particularly the c-Jun N-terminal kinase (JNK) signaling cascade. This pathway is pivotal in cellular responses to stress, apoptosis, inflammation, and development, making JIP-1 (153-163) an essential research target in understanding disease mechanisms and therapeutic interventions.

Recent studies have highlighted the peptide’s ability to inhibit JNK activation by blocking its interaction with upstream activators such as MAPK kinase 7 (MKK7). This inhibition disrupts downstream signaling, reducing pro-inflammatory cytokine production and apoptosis in models of chronic inflammatory and neurodegenerative diseases. The peptide has been investigated as a potential neuroprotective agent, particularly in Alzheimer’s disease and Parkinson’s disease, where excessive JNK signaling contributes to neuronal damage and loss.

In cancer research, JIP-1 (153-163) has gained attention for its ability to modulate apoptosis. Dysregulated JNK activity is a hallmark of many cancers, and by targeting JIP-1 (153-163), researchers aim to restore balance in apoptotic signaling pathways, thereby sensitizing tumor cells to chemotherapeutic agents.

Emerging research also explores the peptide's role in metabolic diseases, including type 2 diabetes and obesity. JNK signaling is implicated in insulin resistance and adipogenesis, and JIP-1 (153-163) may offer therapeutic potential by mitigating these effects. Preclinical studies suggest that the peptide can improve metabolic outcomes by reducing JNK-mediated inflammation in adipose tissue.

Overall, JIP-1 (153-163) serves as a versatile tool in biomedical research, offering insights into stress response modulation and holding promise as a therapeutic target across diverse diseases. Further investigation into its mechanisms may unlock new strategies for combating complex pathologies.

Reference:

Heo, Y. S., Kim, S. K., Seo, C. I., Kim, Y. K., Sung, B. J., Lee, H. S., ... & Yang, C. H. (2004). Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. The EMBO journal, 23(11), 2185-2195.